Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 149Squamous Cell Carcinoma of Head and Neck 76Head and Neck Neoplasms 75Stomach Neoplasms 52Lung Neoplasms 52Esophageal Neoplasms 34Neoplasms 33Uterine Cervical Neoplasms 32Urinary Bladder Neoplasms 32Carcinoma, Squamous Cell 27Parkinson Disease 4, Autosomal Dominant Lewy Body 26Neoplasm Metastasis 26Small Cell Lung Carcinoma 23Breast Neoplasms 23Cholangiocarcinoma 21Carcinoma 19Ovarian Neoplasms 14Adenocarcinoma Of Esophagus 14Triple Negative Breast Neoplasms 13Pancreatic Neoplasms 13Oropharyngeal Neoplasms 13Mesothelioma, Malignant 13Adenocarcinoma 13Biliary Tract Neoplasms 12Mesothelioma 11Gallbladder Neoplasms 11Esophageal Squamous Cell Carcinoma 10Carcinoma, Transitional Cell 10Tongue Neoplasms 9Laryngeal Neoplasms 9

Interventions

berzosertib 1Platinum 1Gemcitabine 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Bladder Urothelial Carcinoma × Cisplatin × Clear all
NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡